BioSpace News Archive

Innovent Biologics, Inc. and Incyte today announced that the companies, through their respective subsidiaries, have entered into a strategic collaboration agreement for three clinical-stage product candidates discovered and developed by Incyte—pemigatinib (FGFR1/2/3 inhibitor), itacitinib (JAK1 inhibitor) and parsaclisib (PI3Kδ inhibitor).

Incyte and Innovent Biologics, Inc. today announced that the companies, through their respective subsidiaries, have entered into a strategic collaboration agreement for three clinical-stage product candidates discovered and developed by Incyte—pemigatinib (FGFR1/2/3 inhibitor), itacitinib (JAK1 inhibitor) and parsaclisib (PI3Kδ inhibitor).

OWKIN today announced the world’s largest AI-powered medical research network. The OWKIN Loop Network is comprised of more than 30 prestigious hospitals and research institutions across the US and Europe.

Hudson to Appear in Company’s “For Every Body” Campaign, Launching Dec. 26 and Celebrating All You Gain When You Live Healthier